Repligen Corporation (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Analysts

Repligen Corporation (NASDAQ:RGEN) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $179.6154.

A number of analysts recently weighed in on the stock. Barclays upped their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Canaccord Genuity Group upped their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. UBS Group increased their price objective on Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Jefferies Financial Group set a $160.00 price objective on Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th.

Repligen Stock Performance

Shares of RGEN opened at $169.97 on Thursday. Repligen has a 52-week low of $102.96 and a 52-week high of $182.52. The stock’s 50-day simple moving average is $163.45 and its 200 day simple moving average is $142.41. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The stock has a market capitalization of $9.57 billion, a price-to-earnings ratio of 8,502.75, a price-to-earnings-growth ratio of 2.96 and a beta of 1.12.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The firm had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. During the same period in the prior year, the business posted $0.43 earnings per share. The company’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Research analysts forecast that Repligen will post 1.72 EPS for the current fiscal year.

Insider Activity

In related news, Director Anthony Hunt sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $154.61, for a total value of $3,092,200.00. Following the sale, the director directly owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This trade represents a 19.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO James Bylund sold 2,191 shares of Repligen stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 49,657 shares of company stock worth $7,721,077. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently made changes to their positions in the stock. United Capital Financial Advisors LLC bought a new stake in shares of Repligen during the 3rd quarter worth $368,387,000. Balyasny Asset Management L.P. raised its position in Repligen by 390.6% during the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock valued at $102,557,000 after purchasing an additional 610,837 shares in the last quarter. Congress Asset Management Co. raised its position in Repligen by 241.4% during the fourth quarter. Congress Asset Management Co. now owns 746,306 shares of the biotechnology company’s stock valued at $122,290,000 after purchasing an additional 527,714 shares in the last quarter. Holocene Advisors LP lifted its stake in Repligen by 47.0% during the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after purchasing an additional 440,290 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after purchasing an additional 400,970 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.